Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 5;15:163. doi: 10.1186/s13045-022-01376-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 5 — CAR.CD123-NK cells exert a significant anti-leukaemia activity in an AML xenograft NGS model. A Illustration of experimental setting in which NSG mice were systemically infused with THP-1-FF-Luc.GFP cells and, at the time of leukaemia engraftment, treated with NT-T, CAR.CD123-T, NT-NK and CAR.CD123-NK cells. B Time course of in vivo bioluminescence imaging of the treated NSG mice from Day 0 (Day of effector cells infusion) to Day 50. C Graph shows bioluminescence analysis of each leukaemia-bearing mouse treated with NT-T (black line with circles), CAR.CD123-T (green line with squares), NT-NK (blue line with pentagon) and CAR.CD123-NK (red line with triangles) cells. D One hundred days probability of overall survival (OS) of leukaemia-bearing mice treated with 2 consecutive adoptive transfers of NT-T (black line with circles), CAR.CD123-T (green line with squares), NT-NK (blue line with pentagon) and CAR.CD123-NK (red line with triangles) cells. On the right bottom, the statistical analysis of 100-Day OS of leukaemia-bearing mice treated with 2 consecutive adoptive transfers of NT-T, CAR.CD123-T, NT-NK, and CAR.CD123-NK cells